---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001035"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T07:56:46.748903+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences reports FY2023 net loss of $97.2M; Phase 3 topline data expected year-end 2024

## Summary
- Net loss $97.2M ($2.32/share) vs $76.2M ($1.90) in 2022; R&D expenses $89.4M.
- Cash and equivalents $121.1M at 12/31/23; $21.8M raised in 2024 from warrant exercises.
- Over 555 patients completed Phase 3 studies; topline data for 52-week trial expected year-end 2024.
- Internal investigation found no evidence substantiating allegations of research misconduct.
- Net cash used in operations $82M in 2023; expected $35-45M in H1 2024.

## SEC filing metadata
- accession: 0001171843-24-001035
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184324001035/0001171843-24-001035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184324001035/f8k_022824.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001035
- JSON: https://secwatch.observer/filing/0001171843-24-001035.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001035.txt

## Key facts
- Earnings Releases
  FILANA THERAPEUTICS, INC. reported full year ended December 31, 2023 results: net income net loss of $97.2 million, EPS loss of $2.32 per share.
  - Period: full year ended December 31, 2023
  - Net income: net loss of $97.2 million
  - EPS: loss of $2.32 per share
  - Result: reported results
  source text: Net loss for full year 2023 was $97.2 million, or $2.32 per share, compared to a net loss of $76.2 million, or $1.90 per share, in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000117184324001035/0001171843-24-001035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.